These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 6892512

  • 1. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.
    Teng CS, Yeung RT.
    J Clin Endocrinol Metab; 1980 Jan; 50(1):144-7. PubMed ID: 6892512
    [Abstract] [Full Text] [Related]

  • 2. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N.
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [Abstract] [Full Text] [Related]

  • 3. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 4. The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.
    Bliddal H, Bech K, Siersbaek-Nielsen K, Friis T.
    J Endocrinol Invest; 1983 Aug; 6(4):259-62. PubMed ID: 6139399
    [Abstract] [Full Text] [Related]

  • 5. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease].
    Li J, Gao H, Xu L.
    Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):218-20, 254-5. PubMed ID: 7922762
    [Abstract] [Full Text] [Related]

  • 6. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM, Darke C, Lazarus JH, Hall R, McGregor AM.
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Thyroid stimulating antibodies (TSAb) in patients with Graves' disease undergoing antithyroid drug treatment: indicators of activity of disease.
    Karlsson FA, Dahlberg PA.
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):579-85. PubMed ID: 6895352
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease?
    Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat-Stefanutti A, Orgiazzi J, Allannic H.
    Clin Endocrinol (Oxf); 1984 Sep; 21(3):247-55. PubMed ID: 6148163
    [Abstract] [Full Text] [Related]

  • 12. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM, Allannic H, Genetet N, Gueguen M, Genetet G, Fauchet R, Stefanutti A, Orgiazzi J.
    J Clin Endocrinol Metab; 1986 Jan; 62(1):117-21. PubMed ID: 3484386
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS, Reis LC.
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C, Cerrone D, Harii N, Thornton M, Kohn LD, Dagia NM, Bucci I, Carpentieri M, Di Nenno B, Di Blasio A, Vitti P, Monaco F, Napolitano G.
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [Abstract] [Full Text] [Related]

  • 19. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs.
    Massart C, Orgiazzi J, Maugendre D.
    Clin Chim Acta; 2001 Feb; 304(1-2):39-47. PubMed ID: 11165197
    [Abstract] [Full Text] [Related]

  • 20. Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves' disease.
    Bech K, Nistrup Madsen S.
    Clin Endocrinol (Oxf); 1980 Nov; 13(5):417-24. PubMed ID: 6894411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.